As its clinical use expands, oncologists and neurologists should maintain a high index of suspicion for PRES in any patient presenting with acute neurological symptoms while on VEGF-targeted therapy - even in the absence of hypertension or other classic risk factors. This evidence concerns the gene VEGFA and hypertensive disorder.